UNSPSC 51383903: Flunixin

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C14H11F3N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 356IB1O400, chemically known as 3-pyridinecarboxylic acid, 2-((2-methyl-3-(trifluoromethyl)phenyl)amino)- but generally known as flunixin, which bears US NIH Compound Identifier 38081. European Medicines Agency schedules Flunixin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07711MIG.

UNSPSC 51383903 Flunixin is a Commodity code that in practice encompasses state and local procurement of pharmaceutical products, including naloxone, drug deactivation systems, generic multi-source medications, and over-the-counter products for government health, community health, and pharmacy benefit programs. State and local issuing bodies—including county health departments, state health and human services agencies, and multistate cooperative purchasing alliances—solicit these products through competitive bidding processes (IFB, RFP) and information-gathering phases (RFI) to support public health initiatives, employee health plans, and institutional pharmacy operations. Vendors typically must meet FDA compliance requirements, maintain current Good Manufacturing Practices certification, comply with the Drug Supply Chain Security Act, demonstrate electronic data interchange capability, and hold appropriate insurance coverage including general liability and professional liability policies. Products must meet specified shelf-life requirements and be available through authorized pharmaceutical wholesalers or direct-to-manufacturer arrangements.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 (due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; vendors must include shipping costs and comply with E-Verify requirements, with a two-year initial term and one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program serving state agencies and self-insured health plans outside traditional pharmacy benefit manager arrangements. The Minnesota Department of Administration's Office of State Procurement, administering the Multistate Cooperative Purchasing Alliance, issued RFP S1070000015802 in January 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products for distribution across participating state and local facilities in multiple states including Oregon, requiring vendors to supply through three authorized wholesalers and meet cGMP and DSCSA compliance with a two-year contract term effective July 1, 2026.